Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cross-labeling comments requested

This article was originally published in The Gray Sheet

Executive Summary

FDA Office of Combination Products plans public meeting next spring or summer to gather input on cross-labeling of therapeutic products, according to OCP Director Mark Kramer. At a recent MDUFMA stakeholder meeting, the combo products chief identified cross-labeling as "a very sticky, complex regulatory issue," and said the 2005 meeting would help FDA generate feedback "with an eye toward rulemaking." OCP is considering guidance on the topic (1"The Gray Sheet" Oct. 25, 2004, p. 18). Under FDA's cross-labeling policy, items intended for use with a separate product may be required to carry dual labeling...

You may also be interested in...



Combo Product Guidances On The March; Primary Mode Of Action Clarified

An FDA intercenter task force is working to finalize the proposed rule governing "primary mode of action" for combination products

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

Transformation Into Viatris Not Seen As The Solution Mylan Needs

Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.

UsernamePublicRestriction

Register

MT021300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel